For months, she felt bloated almost every day. Her pants stopped fitting even though the scale barely moved. She got full after half a meal, needed the bathroom more often, and had a low ache in her pelvis that she blamed on stress, perimenopause, and probably gluten. Two different visits produced two different explanations: irritable bowel syndrome, then maybe fibroids. It was nine months before anyone ordered an ultrasound.
That sequence is the central problem with ovarian cancer. Its early symptoms are real, but they are also the most common complaints in general medicine, so they get filed under digestion, hormones or aging. There is no reliable screening test for women at average risk, which means the symptom pattern, and how quickly it gets taken seriously, does most of the work.
None of that means bloating is a crisis. The vast majority of women with these symptoms do not have cancer. What matters is the pattern: symptoms that are new for you, that happen most days, and that have persisted for a few weeks rather than coming and going with your cycle. Here is what ovarian cancer is, which symptoms deserve attention, how it is actually found, why population screening does not work, and what treatment and cost look like in the US.
What Ovarian Cancer Is
Ovarian cancer refers to malignant tumors that arise in or around the ovaries, the two small organs that produce eggs and hormones. Roughly nine out of ten cases are epithelial tumors, which start in the surface tissue. Much less common are germ cell tumors, which tend to occur in younger women, and stromal tumors, which come from hormone-producing tissue and can cause abnormal bleeding.
One of the most significant shifts in the field is the growing evidence that many high-grade epithelial cancers actually begin in the fallopian tube and spread to the ovary. That is not a technicality. It has changed prevention strategy, and it is why removing the fallopian tubes is now discussed as a risk-reduction option in situations where it was not before.
Because the ovaries sit deep in the pelvis with room to grow, tumors can reach a meaningful size before producing clear symptoms. Most estimates indicate that the majority of cases are diagnosed after the disease has spread beyond the ovary, which is the main reason outcomes for this cancer have improved more slowly than for breast or colon cancer.
Risk Factors for Ovarian Cancer
Genetic and Family History
Inherited genetic changes are the strongest known risk factor. Variants in BRCA1 and BRCA2 substantially raise lifetime risk, and they also raise breast cancer risk, which is why the two conditions are assessed together. Lynch syndrome, an inherited condition better known for colorectal cancer risk, also increases ovarian cancer risk. Several other genes, including RAD51C, RAD51D and BRIP1, are now included on standard testing panels.
A family history of ovarian, breast, colorectal or uterine cancer — especially in more than one relative, on the same side of the family, or diagnosed at younger ages — is a reason to ask for genetic counseling. Ashkenazi Jewish ancestry is associated with a higher frequency of certain BRCA variants. That said, many women diagnosed have no family history at all.
Reproductive and Hormonal Factors
- Age is the biggest non-genetic factor; risk rises after menopause, with most diagnoses occurring in women over 50.
- Never having been pregnant, or having a first pregnancy later in life, is associated with modestly higher risk.
- Starting periods early or reaching menopause late, both of which mean more ovulatory cycles over a lifetime.
- Endometriosis is linked to higher risk of certain ovarian cancer subtypes, though the absolute increase for any individual is small.
- Long-term use of menopausal hormone therapy has been associated with a small increase in risk in some studies, which is one of many factors to weigh with your clinician.
- Obesity and smoking are linked to higher risk of some subtypes, and both are modifiable.
Some factors are associated with lower risk, including pregnancy, breastfeeding, having used combined oral contraceptives for several years, and tubal ligation or removal of the fallopian tubes. None of these eliminate risk, and none should be undertaken solely for that purpose without a full discussion of the tradeoffs.
Because endometriosis is both a risk-modifier and a frequent source of overlapping pelvic symptoms, it is worth understanding why endometriosis is so often missed when you are trying to describe persistent pelvic pain accurately to a doctor.
The Symptoms Women Overlook
Ovarian cancer is not silent, but its signals are quiet and easily reassigned to other causes. The four most consistently reported symptoms are bloating, pelvic or abdominal pain, feeling full quickly or having difficulty eating, and urinary urgency or frequency.
- Persistent bloating or a visibly increasing abdominal size that does not fluctuate with your cycle or resolve after a few days.
- Feeling full after only a few bites, or a noticeable drop in appetite that lasts for weeks.
- Pelvic, lower abdominal or low back pressure and discomfort that is present most days.
- Needing to urinate more often or more urgently, without an infection to explain it.
- Changes in bowel habits, particularly new constipation that does not respond to the usual measures.
- Unexplained fatigue, unintended weight loss, or postmenopausal bleeding, all of which warrant prompt evaluation on their own.
The Pattern That Matters
Clinicians who study this describe a useful rule of thumb: symptoms that are new to you, that occur roughly twelve or more days a month, and that have been going on for less than a year are the combination worth investigating. Long-standing, unchanged bloating that you have had since your twenties is a different situation from bloating that started four months ago and has not let up.
The most common misattribution is to digestive conditions. If a diagnosis of irritable bowel syndrome is being offered for the first time after age 50, or if dietary changes are not helping at all, it is reasonable to ask directly: “Can we rule out a gynecologic cause with an exam and an ultrasound?” Keeping a two-week symptom log with dates makes that conversation much more productive than trying to summarize months from memory.
Why There Is No Reliable Screening Test for Ovarian Cancer
This is the question that frustrates people most, and the answer is worth understanding rather than working around.
What the Candidate Tests Can and Cannot Do
CA-125 is a protein measured in blood that is often elevated in ovarian cancer. The problem is that it is neither specific nor sensitive enough for screening. It rises in many benign conditions — endometriosis, fibroids, pelvic inflammation, liver disease, even normal menstruation — and it is often normal in early-stage disease. Used as a screening test in the general population, it produces a large number of false alarms and misses cancers that are actually there.
Transvaginal ultrasound, an imaging test performed with a small probe, can visualize the ovaries well. But it commonly finds cysts and other benign findings, which are extremely common and mostly harmless. Screening healthy women tends to generate follow-up scans and, in some cases, surgeries that turn out to be unnecessary.
Large randomized trials combining CA-125 and ultrasound in average-risk women have not demonstrated a clear reduction in deaths from ovarian cancer, while documenting real harms from false positives and resulting procedures. On that evidence, the US Preventive Services Task Force recommends against routine screening in women who have no symptoms and no high-risk genetic or family history. That recommendation is not about cost; it is about the balance of benefit and harm.
Where Testing Is Appropriate
These tools are genuinely useful in two situations: evaluating a woman who has symptoms or a mass, and monitoring women already known to be at high risk. For BRCA carriers and others with high-risk genetics, some specialists use periodic CA-125 and ultrasound while acknowledging the limits, and discuss risk-reducing surgery as the more effective option. This is a specialist conversation, not a general recommendation. Broader context on how screening decisions are made is covered in this overview of cancer prevention, screening and risk reduction.
It is also worth stating clearly: a Pap test does not screen for ovarian cancer. It screens for cervical cancer. Many women assume a normal Pap covers everything, and that assumption delays evaluation.
How Ovarian Cancer Is Diagnosed
When symptoms prompt an evaluation, the pathway is fairly consistent, though the order can vary.
| Step | What it involves | What it contributes |
|---|---|---|
| Clinical pelvic exam | A physical exam by a primary care clinician or gynecologist | May detect a mass or fluid, though small tumors are often not felt |
| Pelvic and transvaginal ultrasound | Imaging, usually 20 to 40 minutes, no radiation | Characterizes any mass: size, solid vs. cystic, blood flow |
| CA-125 and other blood markers | A standard blood draw | Adds information when a mass is present; interpreted differently before and after menopause |
| CT or MRI | Cross-sectional imaging, often with contrast | Assesses spread within the abdomen and helps plan surgery |
| Referral to a gynecologic oncologist | Consultation with a subspecialist surgeon | Strongly associated with better surgical outcomes; request it before any operation for a suspicious mass |
| Tissue diagnosis | Usually obtained at surgery; sometimes by biopsy or fluid sampling first | Confirms the diagnosis and identifies the exact subtype |
One point deserves emphasis. If imaging suggests a mass that could be cancer, ask to be referred to a gynecologic oncologist before surgery is scheduled. Research has consistently found that when initial surgery is performed by a subspecialist at a center that handles these cases regularly, staging is more complete and outcomes are generally better. This is one of the few decisions a patient can influence directly.
Staging and Treatment Options
Staging describes how far the disease has spread and is usually determined during surgery. Treatment is then built around the stage, the subtype and your overall health.
| Treatment category | What it generally involves | Key considerations |
|---|---|---|
| Surgery | Removal of the tumor and, in most cases, the ovaries, fallopian tubes, uterus and nearby tissue, with staging biopsies | Extent depends on stage and whether fertility preservation is possible; recovery typically several weeks |
| Chemotherapy | Cycles of drug treatment, most often platinum-based combinations, before or after surgery | Side effects are significant but largely manageable and mostly temporary; supportive care matters |
| Targeted therapy | Drugs such as PARP inhibitors and anti-angiogenic agents used in selected cases | Eligibility often depends on genetic and tumor testing results |
| Maintenance therapy | Ongoing treatment after initial therapy to delay recurrence | Requires weighing side effects against benefit over a long period |
| Clinical trials | Access to newer approaches under a research protocol | Worth asking about at diagnosis and at any recurrence, not only as a last resort |
| Palliative and supportive care | Symptom management alongside active treatment | Early involvement is associated with better quality of life; it is not the same as hospice |
Ovarian cancer often responds well to initial treatment but has a real tendency to return, so care is frequently framed as long-term management with periods of treatment and periods of monitoring. Ask your oncologist to explain the plan in those terms so the schedule ahead makes sense.
Genetic Testing: Who Should Have It and What It Changes
Major guidelines now recommend that every woman diagnosed with epithelial ovarian cancer be offered germline genetic testing, regardless of family history. The reason is practical: results can determine eligibility for certain targeted drugs, and they identify relatives who may benefit from screening or prevention.
Testing is also appropriate for women without cancer who have a significant family history. The process usually begins with genetic counseling, then a blood or saliva sample analyzed on a multi-gene panel. Results come back as positive for a harmful variant, negative, or a variant of uncertain significance — and that third category is common and does not mean you have a mutation.
A positive result opens specific options: enhanced breast surveillance, discussion of risk-reducing removal of the fallopian tubes and ovaries after childbearing, and cascade testing for siblings, children and parents. If you are weighing whether to test, this overview of what genetic testing reveals and what it costs is a reasonable starting point, and the overlap with breast risk is why the same families often also review breast health screening and mammogram guidance. Federal law prohibits health insurers and employers from using genetic test results against you, though those protections do not extend to life or long-term care insurance.
Fertility and Quality-of-Life Considerations
For younger women with early-stage disease or certain tumor types, fertility-sparing surgery — removing one ovary and tube while preserving the uterus and the other ovary — is sometimes possible. Whether it is an option depends heavily on subtype and stage, and it needs to be raised before surgery is scheduled, not after. If chemotherapy is planned, ask about egg or embryo preservation and about a referral to a fertility specialist.
When both ovaries are removed before natural menopause, menopause begins immediately and symptoms are typically more abrupt than a gradual transition. Hot flashes, sleep disruption, mood changes, bone density loss and vaginal dryness are all common and all treatable. Whether hormone therapy is appropriate depends on your tumor type and history, so it is a conversation for your oncology team rather than a general rule.
Fatigue, neuropathy in the hands and feet, digestive changes and the anxiety that comes with surveillance testing are the quality-of-life issues patients most often report. Ask specifically about pelvic floor physical therapy, nutrition support, and counseling — these services exist at most cancer centers and are chronically underused.
Costs and Insurance Coverage in the US
Costs depend on your state, hospital system, insurer contract and treatment plan. The ranges below are typical estimates for planning, not price quotes, and individual bills vary widely.
| Service | Typical estimated range | Usual coverage notes |
|---|---|---|
| Gynecology office visit | Roughly $150 to $350 | Covered as a standard visit; copay or deductible applies |
| Pelvic and transvaginal ultrasound | Roughly $250 to $1,200 | Generally covered as diagnostic imaging when symptoms are documented |
| CA-125 blood test | Roughly $50 to $250 | Covered as diagnostic; usually not covered as a screening test in average-risk women |
| CT scan of abdomen and pelvis | Roughly $500 to $3,000 | Covered when medically indicated; may require prior authorization |
| Staging and debulking surgery | Often tens of thousands before insurance | Covered as cancer surgery; surgeon, facility, anesthesia and pathology bill separately |
| Germline genetic testing panel | Roughly $250 to $2,000 list price | Widely covered after a diagnosis or with qualifying family history; labs often cap patient cost |
A few practical moves matter. Confirm network status separately for every provider involved in a surgery. Ask the cancer center for a financial navigator or social worker, who can identify drug assistance and grant programs. Request an itemized bill and review it, since coding errors are common on complex surgical claims. Understand your out-of-pocket maximum, because with a cancer diagnosis you will likely reach it, and knowing the number ahead of time makes planning possible. For general reference, the National Cancer Institute and MedlinePlus maintain plain-language explanations of diagnostic terms, and Mayo Clinic covers what procedures involve.
Prevention and Risk Reduction
- Know your family history on both sides, including cancers in men, and update it as relatives are diagnosed.
- Ask for genetic counseling if breast, ovarian, uterine or colorectal cancers cluster in your family or occurred before age 50.
- Discuss opportunistic removal of the fallopian tubes if you are already planning a pelvic surgery and have completed childbearing, since the tubes appear to be the origin of many of these cancers.
- Understand that oral contraceptive use for several years is associated with lower ovarian cancer risk, and factor that into contraceptive discussions rather than treating it as a reason on its own.
- Address modifiable factors such as smoking and weight, which influence risk for several cancers, not only this one.
- Track new, persistent pelvic or abdominal symptoms and raise them within weeks rather than months.
When to See a Doctor
Make an appointment if bloating, pelvic pressure, early fullness or urinary urgency are new for you, happening most days, and have lasted two to three weeks or more. See a clinician promptly for any postmenopausal vaginal bleeding, unexplained weight loss, or a rapidly enlarging abdomen. If you are told your symptoms are digestive but they are not improving with treatment, it is entirely appropriate to ask for a pelvic exam and ultrasound. Broader guidance on preventive visits is available in this women’s health guide. Advocating for one imaging test is a small ask, and it is often what shortens the delay.
Frequently Asked Questions
Does bloating always mean ovarian cancer?
No, and it usually does not. Bloating is one of the most common symptoms in general medicine and is far more often caused by diet, irritable bowel syndrome, constipation, hormonal fluctuation or fibroids. What raises concern is bloating that is new for you, present most days for several weeks, not tied to your cycle, and accompanied by early fullness, pelvic pressure or urinary changes. That combination is worth evaluating with an exam and an ultrasound.
Why is there no routine screening test for ovarian cancer?
Because the available tests do not perform well enough in healthy women. CA-125 rises in many benign conditions and is often normal in early disease, while ultrasound frequently detects harmless cysts. Large trials of both tools together have not shown a clear reduction in deaths in average-risk women, but did show harms from false positives and unnecessary surgery. Screening is reserved for women with high-risk genetics, managed by a specialist.
Can a Pap smear detect ovarian cancer?
No. A Pap test samples cells from the cervix and is designed to detect cervical cell changes and HPV, not ovarian tumors. A normal Pap result says nothing about your ovaries. This is a very common misunderstanding and it contributes to delays, because women assume their annual exam has already ruled it out. If you have persistent pelvic symptoms, say so directly and ask what test would evaluate the ovaries specifically.
Should I get BRCA testing if my grandmother had breast cancer?
One relative with breast cancer at an older age is usually not enough on its own, but it is worth a conversation. Genetic counselors look at the whole pattern: how many relatives, which cancers, how young they were, whether it is the same side of the family, and ancestry. Ask your primary care clinician or gynecologist for a referral to genetic counseling, which can assess your family history properly and tell you whether testing is likely to be informative.
Is ovarian cancer hereditary?
A meaningful minority of cases are linked to inherited variants, most often BRCA1, BRCA2 or Lynch syndrome genes, but the majority occur in women with no known inherited cause. That is why family history is useful for identifying higher-risk women, yet not reassuring when it is absent. Current guidelines recommend offering genetic testing to everyone diagnosed with epithelial ovarian cancer, both to guide treatment options and to inform relatives.
The Bottom Line
Ovarian cancer earns its reputation for being hard to catch early, but it is not undetectable and it is not silent. Because there is no reliable screening test for women at average risk, the practical tools are knowing your family history, getting genetic counseling if that history warrants it, and paying attention to a specific symptom pattern: new bloating, early fullness, pelvic pressure or urinary urgency happening most days for several weeks. If that describes you, ask for a pelvic exam and an ultrasound rather than waiting out another dietary trial. If a suspicious mass is found, ask for a referral to a gynecologic oncologist before any surgery is scheduled. Most women with these symptoms will not have cancer, and getting checked is what lets you stop wondering.
This article is for general information only and is not a substitute for professional medical advice, diagnosis, or treatment. Always talk to a qualified healthcare provider about your own symptoms, medications, and treatment options.
